UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X] **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2018

OR

[ ] **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number: 000-09165

STRYKER CORPORATION
(Exact name of registrant as specified in its charter)

Michigan	**38-1239739**
(State of incorporation)	(I.R.S. Employer Identification No.)
2825 Airview Boulevard Kalamazoo, Michigan	**49002**
(Address of principal executive offices)	(Zip Code)

(269) 385-2600
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES [X] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[X]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Small reporting company	[ ]
		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES [ ] NO [X]

There were 374,187,286 shares of Common Stock, $0.10 par value, on September 30, 2018.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Stryker Corporation and Subsidiaries
CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)

	Three Months		Nine Months	
	2018	2017	2018	2017
Net sales	$ 3,242	$ 3,006	$ 9,805	$ 8,973
Cost of sales	1,087	1,022	3,323	3,034
Gross profit	$ 2,155	$ 1,984	$ 6,482	$ 5,939
Research, development and engineering expenses	221	198	641	582
Selling, general and administrative expenses	1,242	1,103	3,668	3,335
Recall charges	4	66	10	164
Amortization of intangible assets	112	92	324	275
Total operating expenses	$ 1,579	$ 1,459	$ 4,643	$ 4,356
Operating income	$ 576	$ 525	$ 1,839	$ 1,583
Other income (expense), net	(42)	(54)	(140)	(169)
Earnings before income taxes	$ 534	$ 471	$ 1,699	$ 1,414
Income taxes	(56)	37	214	145
Net earnings	$ 590	$ 434	$ 1,485	$ 1,269
Net earnings per share of common stock:				
Basic net earnings per share of common stock	$ 1.58	$ 1.16	$ 3.97	$ 3.39
Diluted net earnings per share of common stock	$ 1.55	$ 1.14	$ 3.90	$ 3.34
Weighted-average shares outstanding (in millions):				
Basic	374.1	374.2	374.0	373.8
Effect of dilutive employee stock options	6.1	6.0	6.4	6.0
Diluted	380.2	380.2	380.4	379.8
Cash dividends declared per share of common stock	$ 0.470	$ 0.425	$ 1.410	$ 1.275

Anti-dilutive shares excluded from the calculation of dilutive employee stock options were de minimis in all periods.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)

	Three Months		Nine Months	
	2018	2017	2018	2017
Net earnings	$ 590	$ 434	$ 1,485	$ 1,269
Other comprehensive income (loss), net of tax:				
Marketable securities	—	(3)	(1)	(3)
Pension plans	(3)	14	(1)	4
Unrealized gains (losses) on designated hedges	6	(6)	23	(7)
Financial statement translation	(50)	87	(72)	269
Total other comprehensive income (loss), net of tax	$ (47)	$ 92	$ (51)	$ 263
Comprehensive income	$ 543	$ 526	$ 1,434	$ 1,532

See accompanying notes to Consolidated Financial Statements.

CONSOLIDATED BALANCE SHEETS

	September 30 2018 (Unaudited)	December 31 2017
Assets		
Current assets		
Cash and cash equivalents	$ 1,918	$ 2,542
Marketable securities	292	251
Accounts receivable, less allowance of $62 ($59 in 2017)	2,076	2,198
Inventories:		
Materials and supplies	614	528
Work in process	174	148
Finished goods	2,105	1,789
Total inventories	**$ 2,893**	**$ 2,465**
Prepaid expenses and other current assets	739	537
Total current assets	**$ 7,918**	**$ 7,993**
Property, plant and equipment:		
Land, buildings and improvements	976	936
Machinery and equipment	3,176	2,864
Total property, plant and equipment	$ 4,152	$ 3,800
Less accumulated depreciation	1,974	1,825
Property, plant and equipment, net	**$ 2,178**	**$ 1,975**
Goodwill	7,634	7,168
Other intangibles, net	3,463	3,477
Other noncurrent assets	891	1,584
Total assets	**$ 22,084**	**$ 22,197**
Liabilities and shareholders' equity		
Current liabilities		
Accounts payable	$ 563	$ 487
Accrued compensation	748	838
Income taxes	100	143
Dividend payable	176	178
Accrued recall expenses	111	196
Accrued expenses and other liabilities	1,180	1,011
Current maturities of debt	1,275	632
Total current liabilities	**$ 4,153**	**$ 3,485**
Long-term debt, excluding current maturities	5,928	6,590
Income taxes	1,251	1,261
Other noncurrent liabilities	892	881
Total liabilities	**$ 12,224**	**$ 12,217**
Shareholders' equity		
Common stock, $0.10 par value	37	37
Additional paid-in capital	1,535	1,496
Retained earnings	8,892	8,986
Accumulated other comprehensive loss	(604)	(553)
Total Stryker shareholders' equity	**$ 9,860**	**$ 9,966**
Noncontrolling interest	—	14
Total shareholders' equity	**$ 9,860**	**$ 9,980**
Total liabilities and shareholders' equity	**$ 22,084**	**$ 22,197**

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Nine Months	
	2018	2017
Operating activities		
Net earnings	**$ 1,485**	**$ 1,269**
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation	223	198
Amortization of intangible assets	324	275
Share-based compensation	87	85
Recall charges	10	164
Changes in operating assets and liabilities:		
Accounts receivable	119	72
Inventories	(439)	(322)
Accounts payable	57	(2)
Accrued expenses and other liabilities	(40)	(97)
Recall-related payments	(89)	(492)
Income taxes	(231)	(7)
Other, net	58	(263)
Net cash provided by operating activities	**$ 1,564**	**$ 880**
Investing activities		
Acquisitions, net of cash acquired	(770)	(712)
Purchases of marketable securities	(214)	(85)
Proceeds from sales of marketable securities	173	56
Purchases of property, plant and equipment	(418)	(412)
Net cash used in investing activities	**$ (1,229)**	**$ (1,153)**
Financing activities		
Payments on short-term borrowings, net	(8)	(198)
Proceeds from issuance of long-term debt	595	498
Payments on long-term debt	(600)	—
Dividends paid	(528)	(477)
Repurchases of common stock	(300)	(230)
Cash paid for taxes from withheld shares	(104)	(83)
Payments to purchase noncontrolling interest	(14)	—
Other financing, net	8	(32)
Net cash used in financing activities	**$ (951)**	**$ (522)**
Effect of exchange rate changes on cash and cash equivalents	(8)	71
Change in cash and cash equivalents	**$ (624)**	**$ (724)**
Cash and cash equivalents at beginning of period	2,542	3,316
Cash and cash equivalents at end of period	**$ 1,918**	**$ 2,592**

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 3

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries (the "Company," "we," us" or "our") on September 30, 2018 and the results of operations for the three and nine months 2018. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2017.

Certain prior year amounts have been reclassified to conform with current year presentation in our Consolidated Statements of Earnings, Consolidated Statements of Cash Flows and Note 10.

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

In August 2018 the FASB issued ASU 2018-15, *Intangibles - Goodwill and Other - Internal Use Software - Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*, which amends the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract to align with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. We are in the process of evaluating the impact on our Consolidated Financial Statements and the timing of adoption of this update.

In August 2017 the FASB issued ASU 2017-12, *Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities*, which amends and simplifies hedge accounting guidance, as well as improves presentation and disclosure to align the economic effects of risk management strategies in the financial statements. The update is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We have performed a preliminary assessment of the impact from this update and do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. We plan to adopt this update on January 1, 2019.

In February 2016 the FASB issued ASU 2016-02, *Leases*, in July 2018 issued ASU 2018-10, *Codification Improvements* to Topic 842, *Leases* and in August 2018 issued ASU 2018-11 *Leases - Targeted Improvements* (ASU 2018-11). These updates require an entity to recognize assets and liabilities on the balance sheet for leases with terms greater than 12 months. We are in the process of evaluating the impact on our Consolidated Financial Statements and anticipate most of our leases, as well as some service contracts, will result in the recognition of right of use assets and corresponding lease liabilities on our Consolidated Balance Sheets. We do not anticipate adoption of these updates will have a material impact on net earnings or cash flows and continue to assess the impact on our Consolidated Balance Sheets. We have established a project team to lead the evaluation of our lease agreements and other contracts to assess the impact of the new guidance and are in the process of implementing a lease administration application. We plan to adopt these updates on January 1, 2019, electing the additional transition method provided for in ASU 2018-11 by recording a cumulative-effect adjustment to our Consolidated Balance Sheets as of the adoption date.

Accounting Pronouncements Recently Adopted

On January 1, 2018 we adopted ASU 2014-09, *Revenue from Contracts with Customers.* Refer to Note 2 for further information.

On January 1, 2018 we adopted ASU 2016-16, *Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory*, which requires companies to account for the income tax effect of intercompany sales and transfers of assets other than inventory when the transfer occurs. Under previous guidance, we deferred the income tax effects of intercompany transfers of assets until the asset had been sold to an outside party or otherwise recognized. We recorded a $695 cumulative-effect adjustment to decrease the opening balance of retained earnings as of January 1, 2018.

On January 1, 2018 we adopted ASU 2017-07, *Compensation - Retirement Benefits*, which revises the presentation of the elements of net pension benefit costs. We have retrospectively applied the change in presentation of the non-service cost components of net periodic pension cost by reclassifying these amounts to other income (expense), net within our Consolidated Statements of Earnings. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

On January 1, 2018 we adopted ASU 2017-09, *Compensation - Stock Compensation*, which revises the guidance related to changes in terms or conditions of a share-based payment award. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

On January 1, 2018 we adopted ASU 2018-02, *Income Statements - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income*, which was issued in February 2018 and provides guidance allowing for the reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

NOTE 2 - REVENUE RECOGNITION

On January 1, 2018 we adopted ASU 2014-09 *Revenue from Contracts with Customers* (ASC 606) using the modified retrospective method for contracts that were not completed as of January 1, 2018. The cumulative effect of initially applying ASC 606 was an adjustment to decrease the opening balance of retained earnings by $64 as of January 1, 2018.

With the adoption of ASC 606, we elected to apply certain permitted practical expedients. In evaluating the cumulative-effect adjustment to retained earnings, we adopted the standard only for contracts that were not complete as of the date of adoption. For contracts containing elements of variable consideration, we have elected to use the transaction price at the date the contract was deemed complete. For contracts that were modified prior to the adoption date, we have elected to present the aggregate effect of all contract modifications in determining the transaction price and for the allocation to the satisfied and unsatisfied performance obligations.

The impact of ASC 606 on our results of operations for the three and nine months 2018 was not material and related primarily to the reclassification of certain costs previously presented as selling, general and administrative expenses to net sales.

Sales are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. In the United States most of our products and services are marketed directly to doctors, hospitals and other healthcare facilities through company-owned subsidiaries and branches. Our products are also sold in over 85 countries through company-owned sales subsidiaries and branches as well as third-party dealers and distributors.

Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality. A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales returns has been established based on contract terms with our customers and historical business practices. Shipping and handling costs charged to customers are included in net sales.

Our sales continue to be recognized primarily when title to the product, ownership and risk of loss transfer to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In the three and nine months 2018 less than 10% of our sales were recognized as services transferred over time.

We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.

	Three Months		Nine Months	
	2018	2017	2018	2017
Orthopaedics:				
Knees	$ 395	$ 369	$ 1,236	$ 1,149
Hips	316	313	983	955
Trauma and Extremities	376	367	1,152	1,070
Other	84	83	244	234
	$ 1,171	**$ 1,132**	**$ 3,615**	**$ 3,408**
MedSurg:				
Instruments	$ 442	$ 404	$ 1,292	$ 1,190
Endoscopy	443	404	1,335	1,183
Medical	492	464	1,508	1,413
Sustainability	66	64	190	191
	$ 1,443	**$ 1,336**	**$ 4,325**	**$ 3,977**
Neurotechnology and Spine:				
Neurotechnology	$ 435	$ 353	$ 1,282	$ 1,036
Spine	193	185	583	552
	$ 628	**$ 538**	**$ 1,865**	**$ 1,588**
Total	**$ 3,242**	**$ 3,006**	**$ 9,805**	**$ 8,973**

	Three Months 2018		Three Months 2017	
	United States	International	United States	International
Orthopaedics:				
Knees	$ 291	$ 104	$ 270	$ 99
Hips	198	118	194	119
Trauma and Extremities	242	134	237	130
Other	67	17	68	15
	$ 798	**$ 373**	**$ 769**	**$ 363**
MedSurg:				
Instruments	$ 352	$ 90	$ 316	$ 88
Endoscopy	346	97	316	88
Medical	393	99	357	108
Sustainability	66	—	63	—
	$ 1,157	**$ 286**	**$ 1,052**	**$ 284**
Neurotechnology and Spine:				
Neurotechnology	$ 284	$ 150	$ 222	$ 131
Spine	142	52	139	46
	$ 426	**$ 202**	**$ 361**	**$ 177**
Total	**$ 2,381**	**$ 861**	**$ 2,182**	**$ 824**

	Nine Months 2018		Nine Months 2017	
	United States	International	United States	International
Orthopaedics:				
Knees	$ 896	$ 340	$ 838	$ 311
Hips	610	373	601	354
Trauma and Extremities	729	423	693	377
Other	198	46	190	44
	$ 2,433	**$ 1,182**	**$ 2,322**	**$ 1,086**
MedSurg:				
Instruments	$ 1,007	$ 285	$ 927	$ 263
Endoscopy	1,049	286	927	256
Medical	1,158	350	1,099	314
Sustainability	189	1	190	1
	$ 3,403	**$ 922**	**$ 3,143**	**$ 834**
Neurotechnology and Spine:				
Neurotechnology	$ 820	$ 462	$ 660	$ 376
Spine	424	159	421	131
	$ 1,244	**$ 621**	**$ 1,081**	**$ 507**
Total	**$ 7,080**	**$ 2,725**	**$ 6,546**	**$ 2,427**

Orthopaedics

Orthopaedics products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries. Substantially all Orthopaedics sales are recognized when we have received a purchase order and appropriate notification the product has been used or implanted. For certain Orthopaedic products in the "other" category, we recognize sales at a point in time, as well as over time for performance obligations that may include an obligation to complete installation, provide training and ongoing services. These performance obligations are satisfied within one year.

MedSurg

MedSurg products include surgical equipment and surgical navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), reprocessed and remanufactured medical devices (Sustainability) and other medical device products used in a variety of medical specialties. Substantially all MedSurg sales are recognized when a purchase order has been received and control has transferred. For certain Endoscopy, Instruments and Medical services, we may recognize sales over time as we satisfy performance obligations that may include an obligation to complete

installation, provide training and perform ongoing services and are generally performed within one year.

Neurotechnology and Spine

Neurotechnology and Spine products include both neurosurgical and neurovascular devices. Our spinal implant products include cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. Substantially all Neurotechnology and Spine sales are recognized when a purchase order has been received and control has transferred.

Contract Assets and Liabilities

The nature of our products and services do not generally give rise to contract assets as we typically do not incur costs to fulfill a contract before a product or service is provided to a customer. Our costs to obtain contracts are typically in the form of sales commissions paid to employees of Stryker or third-party agents. We have elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been presented within selling, general and administrative expenses. On September 30, 2018 there were no contract assets recorded in our Consolidated Balance Sheets.

Our contract liabilities arise as a result of unearned revenue received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. On January 1, 2018 our contract liabilities were $381, which were reported in accrued expenses and other liabilities and other noncurrent liabilities in our Consolidated Balance Sheets, $43 of which were recognized in sales in the three months 2018 and $201 in the nine months 2018. On September 30, 2018 our contract liabilities were $281.

NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)

Three Months 2018	Marketable Securities	Pension Plans	Hedges	Financial Statement Translation	Total
Beginning	**$ (5)**	**$ (132)**	**$ 45**	**$ (465)**	**$ (557)**
OCI	1	(2)	8	(50)	(43)
Income taxes	—	(2)	(2)	—	(4)
Reclassifications to:					
Cost of sales	—	2	(2)	—	—
Other expense	(1)	—	1	—	—
Income taxes	—	(1)	1	—	—
Net OCI	$ —	$ (3)	$ 6	$ (50)	$ (47)
Ending	**$ (5)**	**$ (135)**	**$ 51**	**$ (515)**	**$ (604)**

Three Months 2017	Marketable Securities	Pension Plans	Hedges	Financial Statement Translation	Total
Beginning	**$ —**	**$ (142)**	**$ 23**	**$ (471)**	**$ (590)**
OCI	(6)	16	(7)	74	77
Income taxes	2	(4)	2	13	13
Reclassifications to:					
Cost of sales	—	2	(1)	—	1
Other income	1	—	—	—	1
Net OCI	$ (3)	$ 14	$ (6)	$ 87	$ 92
Ending	**$ (3)**	**$ (128)**	**$ 17**	**$ (384)**	**$ (498)**

Nine Months 2018	Marketable Securities	Pension Plans	Hedges	Financial Statement Translation	Total
Beginning	**$ (4)**	**$ (134)**	**$ 28**	**$ (443)**	**$ (553)**
OCI	(1)	(6)	32	(84)	(59)
Income taxes	—	1	(8)	12	5
Reclassifications to:					
Cost of sales	—	6	(4)	—	2
Other expense	—	—	1	—	1
Income taxes	—	(2)	2	—	—
Net OCI	$ (1)	$ (1)	$ 23	$ (72)	$ (51)
Ending	**$ (5)**	**$ (135)**	**$ 51**	**$ (515)**	**$ (604)**

Nine Months 2017	Marketable Securities	Pension Plans	Hedges	Financial Statement Translation	Total
Beginning	**$ —**	**$ (132)**	**$ 24**	**$ (653)**	**$ (761)**
OCI	(6)	1	(17)	227	205
Income taxes	2	(1)	5	42	48
Reclassifications to:					
Cost of sales	—	5	7	—	12
Other income	1	—	—	—	1
Income taxes	—	(1)	(2)	—	(3)
Net OCI	$ (3)	$ 4	$ (7)	$ 269	$ 263
Ending	**$ (3)**	**$ (128)**	**$ 17**	**$ (384)**	**$ (498)**

NOTE 4 - DERIVATIVE INSTRUMENTS

Foreign Currency Hedges

We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both long-term intercompany loans payable and forward exchange contracts) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings and cash flow. We do not enter into derivative instruments for speculative purposes. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2017.

September 2018	Designated	Non-Designated	Total
Gross notional amount	**$ 828**	**$ 4,611**	**$ 5,439**
Maximum term in days			586
Fair value:			
Other current assets	$ 16	$ 22	$ 38
Other noncurrent assets	1	1	2
Other current liabilities	(3)	(15)	(18)
Total fair value	**$ 14**	**$ 8**	**$ 22**

December 2017	Designated	Non-Designated	Total
Gross notional amount	**$ 1,104**	**$ 4,767**	**$ 5,871**
Maximum term in days			548
Fair value:			
Other current assets	$ 11	$ 4	$ 15
Other noncurrent assets	1	—	1
Other current liabilities	(7)	(29)	(36)
Other noncurrent liabilities	(1)	—	(1)
Total fair value	**$ 4**	**$ (25)**	**$ (21)**

In the nine months 2018 we terminated our net investment hedges. The amounts related to settled net investment hedges will be subsequently recognized to other income (expense), net when the hedged investment is either sold or substantially liquidated.

We are exposed to credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument.

Dollar amounts are in millions except per share amounts or as otherwise specified. 6

Net Currency Exchange Rate Gains (Losses)

	Three Months		Nine Months	
Recorded in:	**2018**	**2017**	**2018**	**2017**
Cost of sales	$ 2	$ 1	$ 4	$ (7)
Other income (expense), net	1	(2)	(3)	(6)
Total	**$ 3**	**$ (1)**	**$ 1**	**$ (13)**

On September 30, 2018 and December 31, 2017 pretax gains on derivatives designated as hedges recorded in AOCI that are expected to be reclassified to earnings within 12 months of the balance sheet date are $13 and $7. This reclassification is primarily due to the sale of inventory that includes previously hedged purchases. There were no ineffective portions of derivatives that resulted in gains or losses in any of the periods presented.

Interest Rate Risk

In conjunction with our offering of senior unsecured notes in the nine months 2018 we terminated cash flow hedges with gross notional amounts of $600 designated as hedges of our interest rates, the impact of which will be recognized over time as a benefit to interest expense within other income (expense), net.

We also elected to terminate interest rate swaps with gross notional amounts of $500 designated as fair value hedges of underlying fixed rate obligations representing a portion of our $600 unsecured senior notes due in 2024. The remaining fair value is presented in long-term debt and will be recognized in interest expense within other income (expense), net over the term of the debt.

There was no hedge ineffectiveness recorded as a result of these cash flow and fair value hedges in 2018.

NOTE 5 - FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2017.

There were no significant transfers into or out of any level in 2018.

Assets Measured at Fair Value	**September 2018**	**December 2017**
Cash and cash equivalents	$ 1,918	$ 2,542
Trading marketable securities	130	121
Level 1 - Assets	**$ 2,048**	**$ 2,663**
Available-for-sale marketable securities:		
Corporate and asset-backed debt securities	$ 53	$ 125
Foreign government debt securities	112	2
United States agency debt securities	2	27
United States Treasury debt securities	33	70
Certificates of deposit	92	27
Total available-for-sale marketable securities	$ 292	$ 251
Foreign currency exchange forward contracts	40	15
Interest rate swap asset	—	49
Level 2 - Assets	**$ 332**	**$ 315**
Total assets measured at fair value	**$ 2,380**	**$ 2,978**

Liabilities Measured at Fair Value	**September 2018**	**December 2017**
Deferred compensation arrangements	$ 130	$ 121
Level 1 - Liabilities	**$ 130**	**$ 121**
Foreign currency exchange forward contracts	$ 18	$ 37
Level 2 - Liabilities	**$ 18**	**$ 37**
Contingent consideration:		
Beginning	$ 32	$ 86
Additions	78	3
Change in estimate	—	2
Settlements	(9)	(59)
Ending	$ 101	$ 32
Level 3 - Liabilities	**$ 101**	**$ 32**
Total liabilities measured at fair value	**$ 249**	**$ 190**

Fair Value of Available for Sale Securities by Maturity

	September 2018	**December 2017**
Due in one year or less	$ 140	$ 107
Due after one year through three years	$ 152	$ 144

On September 30, 2018 and December 31, 2017 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income recorded in other income (expense), net, was $29 and $15 in the three months and was $79 and $38 in the nine months 2018 and 2017.

Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. We do not consider these investments to be other-than-temporarily impaired on September 30, 2018. On September 30, 2018 substantially all our investments with unrealized losses that were not deemed to be other-than-temporarily impaired were nominal and were in a continuous unrealized loss position for less than 12 months.

Securities in a Continuous Unrealized Loss Position

	Number of Investments	**Fair Value**
Corporate and asset-backed	116	$ 87
Foreign government	1	2
United States agency	14	24
United States Treasury	39	86
Certificates of deposit	32	48
Total	**202**	**$ 247**

NOTE 6 - CONTINGENCIES AND COMMITMENTS

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters that are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results.

Dollar amounts are in millions except per share amounts or as otherwise specified. 7

We are self-insured for product liability claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. On November 3, 2014 we announced that we had entered into a settlement agreement to compensate eligible United States patients who had revision surgery to replace their Rejuvenate and/or ABG II Modular-Neck hip stem prior to that date and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, some lawsuits will remain and we will continue to defend against them. Based on the information that has been received, the actuarially determined range of probable loss to resolve this matter globally is currently estimated to be approximately $2,077 to $2,318 ($2,309 to $2,550 before $232 of third-party insurance recoveries). We recognized additional charges to earnings of $4 in the three and nine months 2018, representing the excess of the minimum of the range over the previously-recorded reserves. The final outcome of this matter is dependent on many factors that are difficult to predict including the number of enrollees in the settlement program and the total awards to them, the number and costs of patients not eligible for the settlement program who seek testing and treatment services and require revision surgery and the number and actual costs to resolve the remaining lawsuits. Accordingly, the ultimate cost to resolve this entire matter globally may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

In 2010 we filed a lawsuit in federal court against Zimmer Biomet Holdings, Inc. (Zimmer), alleging that a Zimmer product infringed on three of our patents. In 2013 following a jury trial favorable to us, the trial judge entered a final judgment that, among other things, awarded us damages of $76 and ordered Zimmer to pay us enhanced damages. Zimmer appealed this ruling. In December 2014 the Federal Circuit affirmed the damages awarded to us, reversed the order for enhanced damages and remanded the issue of attorney fees to the trial court. In May 2015 the trial court entered a stipulated judgment that, among other things, required Zimmer to pay us the base amount of damages and interest, while the issues of enhanced damages and attorney fees continue to be pursued. In June 2015 we recorded a $54 gain, net of legal costs, which was recorded within selling, general and administrative expenses. On June 13, 2016 the United States Supreme Court vacated the decision of the Federal Circuit that reversed our judgment for enhanced damages and remanded the case to the Federal Circuit to reconsider the issue. On September 12, 2016 the Federal Circuit issued an opinion that, among other things, remanded the issue of enhanced damages to the trial court. On July 12, 2017 the trial court reaffirmed its award of enhanced damages and entered a judgment of $164 in our favor. On July 24, 2017 Zimmer filed a notice of appeal of this decision.

NOTE 7 - ACQUISITIONS

We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. In the nine months 2018 and 2017 cash paid for acquisitions, net of cash acquired, was $770 and $712.

On October 23, 2018 we completed the acquisition of Invuity, Inc. (Invuity) for $7.40 per share, or an aggregate purchase price of approximately $230. Invuity is the leader in advanced photonics and single-use, lighted instruments that deliver enhanced visualization for a wide variety of clinical applications including orthopaedic and spine surgery, general surgery, and women's health procedures, and is a recent entrant into the enhanced energy market. Invuity will be integrated into our Instruments business within MedSurg.

On October 1, 2018 we completed the acquisition of HyperBranch Medical Technology, Inc. (HyperBranch) for an aggregate purchase price of approximately $220. HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels. Its Adherus AutoSpray Dural Sealant product is one of only two FDA-approved dural sealants on the market. HyperBranch will be integrated into our Neurotechnology business within Neurotechnology and Spine.

In August 2018 we announced a definitive agreement to acquire all the issued and outstanding shares of common stock of K2M Group Holdings, Inc. (K2M) for $27.50 per share, or an aggregate purchase price of approximately $1,400. K2M is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. We expect the acquisition to close in the fourth quarter 2018, subject to expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, approval of the merger by K2M's stockholders and other customary closing conditions. K2M will be integrated into our Spine business within Neurotechnology and Spine.

In February 2018 we completed the acquisition of Entellus Medical, Inc. (Entellus) for $24.00 per share, or an aggregate purchase price of $697, net of cash acquired. Entellus is focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of various ear, nose and throat (ENT) disease states. Entellus is part of our Neurotechnology business within Neurotechnology and Spine. Goodwill attributable to the acquisition of Entellus is not deductible for tax purposes.

In September 2017 we completed the acquisition of NOVADAQ Technologies Inc. (NOVADAQ) for an aggregate purchase price of $674, net of cash acquired. NOVADAQ is a leading developer of fluorescence imaging technology that provides surgeons with visualization of blood flow in vessels and related tissue perfusion in cardiac, cardiovascular, gastrointestinal, plastic, microsurgical, and reconstructive procedures. NOVADAQ is part of our Endoscopy business within the MedSurg segment. Goodwill attributable to the acquisition of NOVADAQ is not deductible for tax purposes.

The purchase price allocation for Entellus is preliminary and is based on estimates and assumptions that are subject to change within the measurement period. The purchase price allocation for the acquisition of NOVADAQ was completed in the nine months 2018.

Purchase Price Allocation of Acquired Net Assets

	2018	2017
	Entellus	NOVADAQ
Tangible assets:		
Accounts receivable	$ 17	$ 11
Inventory	14	25
Other assets	72	7
Contingent consideration	(78)	—
Other liabilities	(92)	(56)
Intangible assets:		
Customer relationship	33	18
Trade name	—	1
Developed technology and patents	256	141
Goodwill	475	527
Purchase price, net of cash acquired	**$ 697**	**$ 674**
Weighted-average life of intangible assets	16	15

Estimated Amortization Expense

Remainder of 2018	2019	2020	2021	2022
$ 105	$ 384	$ 349	$ 338	$ 331

NOTE 8 - DEBT AND CREDIT FACILITIES

In March 2018 we issued $600 of senior unsecured notes with a coupon of 3.650% due on March 7, 2028 (the notes). Our annual interest expense arising from the issuance of the notes will be reduced by the benefit from the cash flow hedges that were terminated in conjunction with the issuance. Refer to Note 4 for further information.

In April 2018 we repaid $600 of our senior unsecured notes with a coupon of 1.300%.

Our commercial paper program allows us to have a maximum of $1,500 in commercial paper outstanding with maturities up to 397 days from the date of issuance. On September 30, 2018 there were no amounts outstanding under our commercial paper program.

We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. In August 2018 we extended for an additional two years the maturity date of our $1,500 Credit Agreement, which now matures on August 19, 2023. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on September 30, 2018.

Summary of Total Debt		September 2018	December 2017
Senior unsecured notes:			
Rate	**Due**		
1.300%	April 1, 2018	$ —	$ 600
1.800%	January 15, 2019	500	499
2.000%	March 8, 2019	749	748
4.375%	January 15, 2020	499	498
2.625%	March 15, 2021	747	746
3.375%	May 15, 2024	584	598
3.375%	November 1, 2025	746	745
3.500%	March 15, 2026	989	988
3.650%	March 7, 2028	595	—
4.100%	April 1, 2043	391	391
4.375%	May 15, 2044	395	394
4.625%	March 15, 2046	980	980
Other		28	35
Total debt		**$ 7,203**	**$ 7,222**
Less current maturities of debt		1,275	632
Total long-term debt		**$ 5,928**	**$ 6,590**
Unamortized debt issuance costs		$ 39	$ 39
Available borrowing capacity		$ 1,553	$ 1,547
Fair value of senior unsecured notes		$ 7,118	$ 7,521

The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that considered the underlying terms of the debt instruments. Substantially all our debt is classified within Level 2 of the fair value hierarchy.

NOTE 9 - INCOME TAXES

Our effective tax rates were (10.5)% and 7.9% in the three months 2018 and 2017. The decrease in the effective tax rate was primarily due to adjustments related to the Tax Cuts and Jobs Act (the Act) of 2017.

Our effective tax rates were 12.6% and 10.3% in the nine months 2018 and 2017. The increase in the effective income tax rate was primarily due to adjustments related to the Act and restructuring-related activities to integrate recent acquisitions.

In December 2017 we recorded a provisional transition tax charge and a change in deferred tax accounts associated with the Act. Subsequent to the Act being signed into legislation, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 to provide guidance that allows provisional amounts associated with the Act to be updated during a measurement period ending December 22, 2018. Our accounting for the impact of the Act is not complete and the final impact of the Act may differ from our estimates due to changes in interpretation of the Act, additional legislative action, or guidance issued by tax authorities or regulatory bodies.

NOTE 10 - SEGMENT INFORMATION

	Three Months		Nine Months	
	2018	2017	2018	2017
Orthopaedics	$ 1,171	$ 1,132	$ 3,615	$ 3,408
MedSurg	1,443	1,336	4,325	3,977
Neurotechnology and Spine	628	538	1,865	1,588
Net sales	**$ 3,242**	**$ 3,006**	**$ 9,805**	**$ 8,973**
Orthopaedics	$ 397	$ 390	$ 1,263	$ 1,178
MedSurg	341	272	968	841
Neurotechnology and Spine	173	157	532	446
Segment operating income	**$ 911**	**$ 819**	**$ 2,763**	**$ 2,465**
Items not allocated to segments:				
Corporate and other	(104)	(89)	(291)	(265)
Acquisition and integration-related charges	(8)	(11)	(49)	(29)
Amortization of purchased intangible assets	(112)	(92)	(324)	(275)
Restructuring-related and other charges	(39)	(36)	(124)	(119)
European Medical Devices Regulation	(2)	—	(5)	—
Rejuvenate and other recall-related matters	(4)	(66)	(10)	(164)
Regulatory and legal matters	(66)	—	(121)	(30)
Consolidated operating income	**$ 576**	**$ 525**	**$ 1,839**	**$ 1,583**

There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2017.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ABOUT STRYKER

Stryker Corporation ("we" or "our") is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.

We segregate our operations into three reportable business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. Orthopaedics products consist primarily of implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg products include surgical equipment and surgical navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), reprocessed and remanufactured medical devices (Sustainability) and other medical device products used in a variety of medical specialties. Neurotechnology and Spine products include neurosurgical, neurovascular and spinal implant devices.

Overview of the Three and Nine Months

In the three months 2018 we achieved sales growth of 7.9%. Excluding the impact of acquisitions and the adoption of Accounting Standards Update 2014-09, *Revenue From Contracts with Customers*, as well as related amendments (ASC 606), sales grew 7.9% in constant currency. We reported operating income margin of 17.8% in the three months 2018, net earnings of $590 and net earnings per diluted share of $1.55. Excluding the impact of certain items, we expanded adjusted operating income margin 60 basis points to 24.9%, with adjusted net earnings(1) of $643 and growth of 11.2% in adjusted net earnings per diluted share(1).

In the nine months 2018 we achieved sales growth of 9.3%. Excluding the impact of acquisitions and the adoption of ASC 606, sales grew 7.6% in constant currency. We reported operating income margin of 18.8% in the nine months 2018, net earnings of $1,485 and net earnings per diluted share o f $3.90. Excluding the impact of certain items, we expanded adjusted operating income margin 70 basis points to 25.2%, with adjusted net earnings(1) of $1,951 and growth of 13.2% in adjusted net earnings per diluted share(1).

Recent Developments

In August 2018 we announced a definitive agreement to acquire all the issued and outstanding shares of common stock of K2M Group Holdings, Inc. (K2M) for $27.50 per share, or an aggregate purchase price of approximately $1,400. K2M is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. We expect the acquisition to close in the fourth quarter 2018, subject to expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, approval of the merger by K2M's stockholders and other customary closing conditions. K2M will be integrated into our Spine business within Neurotechnology and Spine.

In March 2018 we issued $600 of senior unsecured notes with a coupon of 3.650% due on March 7, 2028. In April 2018 we repaid $600 of our senior unsecured notes with a coupon of 1.300%. Refer to Note 8 to our Consolidated Financial Statements for further information.

In February 2018 we completed the acquisition of Entellus Medical, Inc. (Entellus) for $24.00 per share, or an aggregate purchase price of $697, net of cash acquired. Entellus is focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of various ear, nose and throat (ENT) disease states. Entellus is part of our Neurotechnology business within the Neurotechnology and Spine segment. Refer to Note 7 to our Consolidated Financial Statements for further information.

(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-GAAP financial measures used in this report and a reconciliation to the most directly comparable GAAP financial measure.

RESULTS OF OPERATIONS

	Three Months					Nine Months				
			Percent Net Sales		Percentage			Percent Net Sales		Percentage
	2018	2017	2018	2017	Change	2018	2017	2018	2017	Change
Net sales	$ 3,242	$ 3,006	100.0 %	100.0 %	7.9 %	$ 9,805	$ 8,973	100.0 %	100.0 %	9.3 %
Gross profit	2,155	1,984	66.5	66.0	8.6	6,482	5,939	66.1	66.2	9.1
Research, development and engineering expenses	221	198	6.8	6.6	11.6	641	582	6.5	6.5	10.1
Selling, general and administrative expenses	1,242	1,103	38.3	36.7	12.6	3,668	3,335	37.4	37.2	10.0
Recall charges	4	66	0.1	2.2	(93.9)	10	164	0.1	1.8	(93.9)
Amortization of intangible assets	112	92	3.5	3.1	21.7	324	275	3.3	3.1	17.8
Other income (expense), net	(42)	(54)	(1.3)	(1.8)	(22.2)	(140)	(169)	(1.4)	(1.9)	(17.2)
Income taxes	(56)	37			(251.4)	214	145			47.6
Net earnings	$ 590	$ 434	18.2 %	14.4 %	35.9 %	$ 1,485	$ 1,269	15.1 %	14.1 %	17.0 %
Net earnings per diluted share	$ 1.55	$ 1.14			36.0 %	$ 3.90	$ 3.34			16.8 %
Adjusted net earnings per diluted share(1)	$ 1.69	$ 1.52			11.2 %	$ 5.13	$ 4.53			13.2 %

Dollar amounts are in millions except per share amounts or as otherwise specified. 10

Geographic and Segment Net Sales

	Three Months				Nine Months			
			Percentage Change				Percentage Change	
	2018	2017	As Reported	Constant Currency	2018	2017	As Reported	Constant Currency
Geographic:								
United States	$ 2,381	$ 2,182	9.1%	9.1%	$ 7,080	$ 6,546	8.2%	8.2%
International	861	824	4.5	7.8	2,725	2,427	12.3	8.9
Total	**$ 3,242**	**$ 3,006**	**7.9%**	**8.8%**	**$ 9,805**	**$ 8,973**	**9.3%**	**8.4%**
Segment:								
Orthopaedics	$ 1,171	$ 1,132	3.4%	4.5%	$ 3,615	$ 3,408	6.1%	5.0%
MedSurg	1,443	1,336	8.0	8.8	4,325	3,977	8.8	8.2
Neurotechnology and Spine	628	538	16.7	17.7	1,865	1,588	17.4	16.2
Total	**$ 3,242**	**$ 3,006**	**7.9%**	**8.8%**	**$ 9,805**	**$ 8,973**	**9.3%**	**8.4%**

Supplemental Net Sales Growth Information

	Three Months							Nine Months						
			Percentage Change							Percentage Change				
					United States	International						United States	International	
	2018	2017	As Reported	Constant Currency	As Reported	As Reported	Constant Currency	2018	2017	As Reported	Constant Currency	As Reported	As Reported	Constant Currency
Orthopaedics:														
Knees	$ 395	$ 369	7.0%	8.3%	7.8 %	5.1 %	9.2 %	$ 1,236	$ 1,149	7.6 %	6.7 %	6.9 %	9.3%	6.2%
Hips	316	313	1.0	2.2	2.1	(0.8)	2.5	983	955	2.9	1.9	1.5	5.4	2.4
Trauma and Extremities	376	367	2.5	3.2	2.1	3.1	5.1	1,152	1,070	7.7	6.0	5.2	12.2	7.5
Other	84	83	1.2	2.7	(1.5)	13.3	19.1	244	234	4.3	3.9	4.2	4.5	4.1
	$ 1,171	**$ 1,132**	**3.4%**	**4.5%**	**3.8 %**	**2.8 %**	**6.0 %**	**$ 3,615**	**$ 3,408**	**6.1 %**	**5.0 %**	**4.8 %**	**8.8%**	**5.4%**
MedSurg:														
Instruments	$ 442	$ 404	9.4%	10.0%	11.4 %	2.3 %	4.2 %	$ 1,292	$ 1,190	8.6 %	7.8 %	8.6 %	8.4%	4.9%
Endoscopy	443	404	9.7	10.8	9.5	10.2	15.0	1,335	1,183	12.8	12.4	13.2	11.7	9.3
Medical	492	464	6.0	6.8	10.1	(8.3)	(4.4)	1,508	1,413	6.7	6.1	5.4	11.5	8.5
Sustainability	66	64	3.1	3.9	4.8	—	15.0	190	191	(0.5)	(0.6)	(0.5)	—	15.7
	$ 1,443	**$ 1,336**	**8.0%**	**8.8%**	**10.0 %**	**0.7 %**	**4.3 %**	**$ 4,325**	**$ 3,977**	**8.8 %**	**8.2 %**	**8.3 %**	**10.6%**	**7.6%**
Neurotechnology and Spine:														
Neurotechnology	$ 435	$ 353	23.2%	24.1%	27.9 %	14.5 %	18.1 %	$ 1,282	$ 1,036	23.7 %	22.3 %	24.2 %	22.9%	18.9%
Spine	193	185	4.3	5.5	2.2	13.0	15.8	583	552	5.6	4.8	0.7	21.4	17.5
	$ 628	**$ 538**	**16.7%**	**17.7%**	**18.0 %**	**14.1 %**	**17.5 %**	**$ 1,865**	**$ 1,588**	**17.4 %**	**16.2 %**	**15.1 %**	**22.5%**	**18.6%**
Total	**$ 3,242**	**$ 3,006**	**7.9%**	**8.8%**	**9.1 %**	**4.5 %**	**7.8 %**	**$ 9,805**	**$ 8,973**	**9.3 %**	**8.4 %**	**8.2 %**	**12.3%**	**8.9%**

Consolidated Net Sales

Consolidated net sales increased 7.9% in the three months 2018 as reported and 8.8% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.9%. Excluding the 1.8% impact of acquisitions and 0.9% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 9.5% from unit volume partially offset by 1.6% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology, instruments, knee, medical and endoscopy products.

Consolidated net sales increased 9.3% in the nine months 2018 as reported and 8.4% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.9%. Excluding the 1.8% impact of acquisitions and 1.0% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 9.0% from unit volume partially offset by 1.4% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology, medical, instruments, knee, endoscopy and trauma and extremities products.

Orthopaedics Net Sales

Orthopaedics net sales increased 3.4% in the three months 2018 as reported and 4.5% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.1%. Excluding the 0.6% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 7.6% from unit volume partially offset by 2.6% due to lower prices. The unit volume increase was primarily due to higher shipments of knee and trauma and extremities products.

Orthopaedics net sales increased 6.1% in the nine months 2018 as reported and 5.0% in constant currency, as foreign currency exchange rates positively impacted net sales by 1.1%. Excluding the 0.5% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 7.8% from unit volume partially offset by 2.4% due to lower prices. The unit volume increase was primarily due to higher shipments of knee and trauma and extremities products.

Dollar amounts are in millions except per share amounts or as otherwise specified. 11

MedSurg Net Sales

MedSurg net sales increased 8.0% in the three months 2018 as reported and 8.8% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.8%. Excluding the 1.5% impact of acquisitions and 1.5% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 9.5% from unit volume partially offset by 0.7% due to lower prices. The unit volume increase was primarily due to higher shipments of instruments, medical and endoscopy products.

MedSurg net sales increased 8.8% in the nine months 2018 as reported and 8.2% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.6%. Excluding the 1.8% impact of acquisitions and 1.6% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 8.5% from unit volume partially offset by 0.5% due to lower prices. The unit volume increase was primarily due to higher shipments of medical, instruments and endoscopy products.

Neurotechnology and Spine Net Sales

Neurotechnology and Spine net sales increased 16.7% in the three months 2018 as reported and 17.7% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.0%. Excluding the 6.5% impact of acquisitions and 0.7% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 13.5% from unit volume partially offset by 1.6% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology products.

Neurotechnology and Spine net sales increased 17.4% in the nine months 2018 as reported and 16.2% in constant currency, as foreign currency exchange rates positively impacted net sales by 1.2%. Excluding the 5.4% impact of acquisitions and 0.7% negative impact from adoption of a new revenue recognition standard, net sales in constant currency increased by 13.0% from unit volume partially offset by 1.5% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology products.

We adopted Accounting Standards Update 2014-09, *Revenue From Contracts with Customers*, as well as related amendments (ASC 606), issued by the Financial Accounting Standards Board on a modified retrospective basis, effective January 1, 2018. Refer to Note 1 and Note 2 to our Consolidated Financial Statements for further information.

The following sales growth data and subsequent analysis have been presented to supplement our discussion and analysis of net sales by quantifying and excluding the impact of the adoption of ASC 606 for our businesses, which related primarily to the reclassification of certain costs previously presented as selling, general and administrative expenses to net sales.

The impact of adopting ASC 606 is expected to continue to have an impact on net sales in 2018. The impact to the 12 months 2017 if ASC 606 was adopted would have resulted in a reduction to net sales of approximately $112 ($28 per quarter).

	Three Months							
					Percentage Change Excluding ASC 606 Impact			
			Percentage Change				International	
	2018	2017	As Reported	Excluding ASC 606 Impact	Constant Currency	United States	Excluding ASC 606 Impact	Constant Currency
Orthopaedics:								
Knees	$ 395	$ 369	7.0%	7.7%	8.7%	8.4 %	5.7 %	9.6 %
Hips	316	313	1.0	1.2	2.5	2.4	(0.6)	2.8
Trauma and Extremities	376	367	2.5	3.2	4.0	3.2	3.1	5.5
Other	84	83	1.2	1.6	2.7	(0.9)	13.1	19.3
	$ 1,171	**$ 1,132**	**3.4%**	**4.0%**	**5.0%**	**4.4 %**	**3.0 %**	**6.3 %**
MedSurg:								
Instruments	$ 442	$ 404	9.4%	10.7%	11.6%	13.7 %	0.3 %	4.3 %
Endoscopy	443	404	9.7	10.8	11.9	11.0	10.4	15.2
Medical	492	464	6.0	7.5	8.5	12.4	(8.1)	(4.2)
Sustainability	66	64	3.1	7.0	7.0	7.0	10.9	15.0
	$ 1,443	**$ 1,336**	**8.0%**	**9.5%**	**10.4%**	**12.0 %**	**0.2 %**	**4.5 %**
Neurotechnology and Spine:								
Neurotechnology	$ 435	$ 353	23.2%	23.8%	24.8%	28.7 %	15.4 %	18.2 %
Spine	193	185	4.3	5.2	5.9	2.4	13.4	16.5
	$ 628	**$ 538**	**16.7%**	**17.4%**	**18.3%**	**18.6 %**	**14.9 %**	**17.8 %**
Total	**$ 3,242**	**$ 3,006**	**7.9%**	**8.8%**	**9.8%**	**10.4 %**	**4.6 %**	**8.1 %**

Dollar amounts are in millions except per share amounts or as otherwise specified. 12

			Nine Months					
			Percentage Change		Percentage Change Excluding ASC 606 Impact			
							International	
	2018	2017	As Reported	Excluding ASC 606 Impact	Constant Currency	United States	Excluding ASC 606 Impact	Constant Currency
Orthopaedics:								
Knees	$ 1,236	$ 1,149	7.6 %	8.0%	7.1%	7.3%	9.8%	6.6%
Hips	983	955	2.9	3.3	2.2	1.9	5.5	2.6
Trauma and Extremities	1,152	1,070	7.7	8.5	6.9	6.3	12.5	8.0
Other	244	234	4.3	4.2	3.9	3.9	5.4	4.2
	$ 3,615	**$ 3,408**	**6.1 %**	**6.6%**	**5.4%**	**5.3%**	**9.2%**	**5.7%**
MedSurg:								
Instruments	$ 1,292	$ 1,190	8.6 %	10.2%	9.5%	10.8%	8.0%	5.0%
Endoscopy	1,335	1,183	12.8	14.2	13.6	14.8	11.8	9.5
Medical	1,508	1,413	6.7	8.3	7.7	7.4	11.5	8.7
Sustainability	190	191	(0.5)	2.5	2.5	2.4	17.3	15.7
	$ 4,325	**$ 3,977**	**8.8 %**	**10.4%**	**9.8%**	**10.3%**	**10.5%**	**7.8%**
Neurotechnology and Spine:								
Neurotechnology	$ 1,282	$ 1,036	23.7 %	24.5%	23.0%	25.3%	23.1%	19.1%
Spine	583	552	5.6	6.1	5.2	1.1	22.1	18.2
	$ 1,865	**$ 1,588**	**17.4 %**	**18.1%**	**16.8%**	**15.8%**	**22.9%**	**18.9%**
Total	**$ 9,805**	**$ 8,973**	**9.3 %**	**10.3%**	**9.4%**	**9.4%**	**12.5%**	**9.1%**

Consolidated Net Sales *(Excluding ASC 606 Impact)*

Consolidated net sales increased 8.8% in the three months 2018 and 9.8% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.0%. Excluding the 1.9% impact of acquisitions net sales in constant currency increased by 9.5% from unit volume partially offset by 1.6% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology, instruments, knee, medical and endoscopy products.

Consolidated net sales increased 10.3% in the nine months 2018 and 9.4% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.9%. Excluding the 1.8% impact of acquisitions net sales in constant currency increased by 9.0% from unit volume partially offset by 1.4% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology, medical, instruments, knee, endoscopy and trauma and extremities products.

Orthopaedics Net Sales *(Excluding ASC 606 Impact)*

Orthopaedics net sales increased 4.0% in the three months 2018 and 5.0% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.0%. Net sales in constant currency increased by 7.6% from unit volume partially offset by 2.6% due to lower prices. The unit volume increase was primarily due to higher shipments of knee and trauma and extremities products.

Orthopaedics net sales increased 6.6% in the nine months 2018 and 5.4% in constant currency, as foreign currency exchange rates positively impacted net sales by 1.2%. Net sales in constant currency increased by 7.8% from unit volume partially offset by 2.4% due to lower prices. The unit volume increase was primarily due to higher shipments of knee and trauma and extremities products.

MedSurg Net Sales *(Excluding ASC 606 Impact)*

MedSurg net sales increased 9.5% in the three months 2018 and 10.4% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.9%. Excluding the 1.6% impact of acquisitions net sales in constant currency increased by 9.5% from unit volume partially offset by 0.7% due to lower prices. The unit volume increase was primarily due to higher shipments of instruments, medical and endoscopy products.

MedSurg net sales increased 10.4% in the nine months 2018 and 9.8% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.6%. Excluding the 1.8% impact of acquisitions net sales in constant currency increased by 8.5% from unit volume partially offset by 0.5% due to lower prices. The unit volume increase was primarily due to higher shipments of medical, instruments and endoscopy products.

Neurotechnology and Spine Net Sales *(Excluding ASC 606 Impact)*

Neurotechnology and Spine net sales increased 17.4% in the three months 2018 and 18.3% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.9%. Excluding the 6.4% impact of acquisitions net sales in constant currency increased by 13.5% from unit volume partially offset by 1.6% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology products.

Neurotechnology and Spine net sales increased 18.1% in the nine months 2018 and 16.8% in constant currency, as foreign currency exchange rates positively impacted net sales by 1.3%. Excluding the 5.3% impact of acquisitions net sales in constant currency increased by 13.0% from unit volume partially offset by 1.5% due to lower prices. The unit volume increase was primarily due to higher shipments of neurotechnology products.

Gross Profit

Gross profit as a percentage of sales in the three months 2018 increased to 66.5% from 66.0% in 2017. Excluding the impact of the items noted below, gross profit increased to 66.3% of sales in the three months 2018 from 66.1% in 2017 primarily due to the impact of adopting ASC 606, partially offset by lower inventory step-up related to recent acquisitions.

Gross profit as a percentage of sales in the nine months 2018 decreased to 66.1% from 66.2% in 2017. Excluding the impact of the items noted below, gross profit decreased to 66.2% of sales in the nine months 2018 from 66.3% in 2017 primarily due to lower selling prices, partially offset by the impact of adopting ASC 606.

			Percent Net Sales	
Three Months	2018	2017	2018	2017
Reported	**$ 2,155**	**$ 1,984**	**66.5 %**	**66.0%**
Inventory stepped-up to fair value	(11)	2	(0.3)	0.1
Restructuring-related and other charges	4	1	0.1	—
Adjusted	**$ 2,148**	**$ 1,987**	**66.3 %**	**66.1%**

Dollar amounts are in millions except per share amounts or as otherwise specified. 13

Nine Months	2018	2017	Percent Net Sales 2018	Percent Net Sales 2017
Reported	**$ 6,482**	**$ 5,939**	**66.1%**	**66.2%**
Inventory stepped-up to fair value	—	2	—	—
Restructuring-related and other charges	9	12	0.1	0.1
European Medical Devices Regulation	1	—	—	—
Adjusted	**$ 6,492**	**$ 5,953**	**66.2%**	**66.3%**

Research, Development and Engineering Expenses

Research, development and engineering expenses increased $23 or 11.6% to 6.8% of sales in the three months 2018 from 6.6% in 2017. In the nine months 2018 these expenses increased $59 or 10.1% to 6.5% of sales, which was flat relative to 2017. Projects to develop new products, investments in new technologies and recent acquisitions contributed to the increased spending levels.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $139 or 12.6% in the three months 2018 and increased as a percentage of sales to 38.3% from 36.7% in 2017. Excluding the impact of the items noted below, expenses decreased to 34.6% of sales in 2018 from 35.2% in 2017, primarily due to leverage from higher sales volumes, the favorable impact from the adoption of ASC 606 and continued focus on our operating expense improvement initiatives, partially offset by the leverage from recent acquisitions.

Selling, general and administrative expenses increased $333 or 10.0% in the nine months 2018 and increased as a percentage of sales to 37.4% from 37.2% in 2017. Excluding the impact of the items noted below, expenses decreased to 34.5% of sales in 2018 from 35.3% in 2017, primarily due to leverage from higher sales volumes, the favorable impact from the adoption of ASC 606 and continued focus on our operating expense improvement initiatives, partially offset by the leverage from recent acquisitions.

Three Months	2018	2017	Percent Net Sales 2018	Percent Net Sales 2017
Reported	**$ 1,242**	**$ 1,103**	**38.3 %**	**36.7 %**
Other acquisition and integration-related	(19)	(9)	(0.6)	(0.3)
Restructuring-related and other charges	(35)	(35)	(1.1)	(1.2)
Regulatory and legal matters	(66)	—	(2.0)	—
Adjusted	**$ 1,122**	**$ 1,059**	**34.6 %**	**35.2 %**

Nine Months	2018	2017	Percent Net Sales 2018	Percent Net Sales 2017
Reported	**$ 3,668**	**$ 3,335**	**37.4 %**	**37.2 %**
Other acquisition and integration-related	(49)	(27)	(0.5)	(0.3)
Restructuring-related and other charges	(115)	(107)	(1.2)	(1.2)
Regulatory and legal matters	(121)	(30)	(1.2)	(0.4)
Adjusted	**$ 3,383**	**$ 3,171**	**34.5 %**	**35.3 %**

Recall Charges

Recall charges were $4 and $66 in the three months and were $10 and $164 in the nine months 2018 and 2017. The decrease in charges were primarily due to the absence of adjustments to the liability for the Rejuvenate and ABG II Modular-Neck hip stems voluntary recalls in 2018. Refer to Note 6 to our Consolidated Financial Statements for further information.

Amortization of Intangible Assets

Amortization of intangible assets was $112 and $92 in the three months and was $324 and $275 in the nine months 2018 and 2017. The increase in 2018 was primarily due to our recent acquisitions. Refer to Note 7 to our Consolidated Financial Statements for further information.

Operating Income

Operating Income increased $51 or 9.7% to 17.8% of net sales in the three months 2018 from 17.5% in 2017. Excluding the impact of the items noted below, operating income increased to 24.9% of sales in 2018 from 24.3% in 2017 primarily due to the benefit from higher sales volumes and a 20 basis point favorable impact from the adoption of ASC 606, partially offset by lower selling prices.

Operating Income increased $256 or 16.2% to 18.8% of net sales in the nine months 2018 from 17.6% in 2017. Excluding the impact of the items noted below, operating income increased to 25.2% of sales in 2018 from 24.5% in 2017 primarily due to the benefit from higher sales volumes and a 20 basis point favorable impact from the adoption of ASC 606, partially offset by lower selling prices.

Three Months	2018	2017	Percent Net Sales 2018	Percent Net Sales 2017
Reported	**$ 576**	**$ 525**	**17.8 %**	**17.5%**
Inventory stepped-up to fair value	(11)	2	(0.3)	0.1
Other acquisition and integration-related	19	9	0.6	0.3
Amortization of purchased intangible assets	112	92	3.4	3.0
Restructuring-related and other charges	39	36	1.2	1.2
European Medical Devices Regulation	2	—	0.1	—
Rejuvenate and other recall-related matters	4	66	0.1	2.2
Regulatory and legal matters	66	—	2.0	—
Adjusted	**$ 807**	**$ 730**	**24.9 %**	**24.3%**

Nine Months	2018	2017	Percent Net Sales 2018	Percent Net Sales 2017
Reported	**$ 1,839**	**$ 1,583**	**18.8%**	**17.6%**
Inventory stepped-up to fair value	—	2	—	—
Other acquisition and integration-related	49	27	0.5	0.3
Amortization of purchased intangible assets	324	275	3.3	3.1
Restructuring-related and other charges	124	119	1.3	1.3
European Medical Devices Regulation	5	—	—	—
Rejuvenate and other recall-related matters	10	164	0.1	1.8
Regulatory and legal matters	121	30	1.2	0.4
Adjusted	**$ 2,472**	**$ 2,200**	**25.2%**	**24.5%**

Other Income (Expense), Net

Other income (expense), net was ($42) and ($54) in the three months and was ($140) and ($169) in the nine months 2018 and 2017. The decrease in 2018 was primarily due to an increase in interest income due to higher interest rates partially offset by higher interest expense due to higher interest rates and slightly higher debt outstanding.

Income Taxes

The effective tax rates were (10.5)% and 7.9% in the three months 2018 and 2017. The decrease in the effective tax rate in the 2018 was primarily due to adjustments related to the Tax Cuts and Jobs Act (the Act) of 2017.

The effective tax rates were 12.6% and 10.3% in the nine months 2018 and 2017. The increase in the effective tax rate in 2018 was due to adjustments related to the Act and restructuring-related activities to integrate recent acquisitions.

Net Earnings

Net earnings increased to $590 or $1.55 per diluted share in the three months 2018 from $434 or $1.14 per diluted share in 2017. Adjusted net earnings per diluted share(1) increased 11.2% to $1.69 in 2018 from $1.52 in 2017. The impact of foreign currency exchange rates on net earnings per diluted share was neutral in 2018 and reduced net earnings per diluted share by approximately $0.01 in 2017.

Dollar amounts are in millions except per share amounts or as otherwise specified. 14

Net earnings increased to $1,485 or $3.90 per diluted share in the nine months 2018 from $1,269 or $3.34 per diluted share in 2017. Adjusted net earnings per diluted share[(1)] increased 13.2% to $5.13 in 2018 from $4.53 in 2017. The impact of foreign currency exchange rates increased net earnings per diluted share by approximately $0.06 in 2018 and reduced net earnings per diluted share by approximately $0.07 in 2017.

			Percent Net Sales	
Three Months	**2018**	**2017**	**2018**	**2017**
Reported	**$ 590**	**$ 434**	**18.2 %**	**14.4 %**
Inventory stepped-up to fair value	(11)	2	(0.3)	0.1
Other acquisition and integration-related	17	6	0.5	0.2
Amortization of purchased intangible assets	92	66	2.8	2.2
Restructuring-related and other charges	31	27	0.9	0.9
European Medical Devices Regulation	2	—	0.1	—
Rejuvenate and other recall-related matters	2	48	0.1	1.6
Regulatory and legal matters	50	(5)	1.5	(0.2)
Tax matters	(130)	—	(4.0)	—
Adjusted	**$ 643**	**$ 578**	**19.8 %**	**19.2 %**

			Percent Net Sales	
Nine Months	**2018**	**2017**	**2018**	**2017**
Reported	**$ 1,485**	**$ 1,269**	**15.1 %**	**14.1%**
Inventory stepped-up to fair value	(4)	2	—	—
Other acquisition and integration-related	41	20	0.4	0.2
Amortization of purchased intangible assets	263	190	2.7	2.1
Restructuring-related and other charges	98	95	1.0	1.1
European Medical Devices Regulation	4	—	0.1	—
Rejuvenate and other recall-related matters	7	123	0.1	1.4
Regulatory and legal matters	92	20	0.9	0.3
Tax matters	(35)	—	(0.4)	—
Adjusted	**$ 1,951**	**$ 1,719**	**19.9 %**	**19.2%**

[(1)]Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth excluding the impact of the adoption of ASC 606; percentage sales growth in constant currency; percentage sales growth in constant currency and excluding the impact of the adoption of ASC 606; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted amortization of intangible assets; adjusted operating income; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and the impact of the adoption of ASC 606, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year results at prior year average foreign currency exchange rates excluding the impact of acquisitions and the adoption of ASC 606.

To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing and may not be indicative of our past and future performance. The following are examples of the types of adjustments that may be included in a period:

1. *Acquisition and integration-related costs*. Costs related to integrating recently acquired businesses and specific costs (e.g., inventory step-up and deal costs) related to the consummation of the acquisition process.
2. *Amortization of purchased intangible assets*. Periodic amortization expense related to purchased intangible assets.
3. *Restructuring-related and other charges*. Costs associated with the termination of sales relationships in certain countries, workforce reductions, elimination of product lines, weather-related asset impairments and associated costs and other restructuring-related activities.
4. *European Medical Devices Regulation*. Costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the European Union's regulation for medical devices.
5. *Rejuvenate and other recall-related matters*. Our best estimate of the minimum end of the range of probable loss to resolve the Rejuvenate recall and other recall-related matters.
6. *Regulatory and legal matters*. Our best estimate of the minimum of the range of probable loss to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
7. *Tax matters*. Charges represent the impact of accounting for certain significant and discrete tax items, including adjustments related to the Act.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, operating income, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures at the end of the discussion of Results of Operations below. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The weighted-average diluted shares outstanding used in the calculation of non-GAAP net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

Dollar amounts are in millions except per share amounts or as otherwise specified. 15

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Three Months 2018	Gross Profit	Selling, General & Administrative Expenses	Amortization of Intangible Assets	Operating Income	Net Earnings	Effective Tax Rate	Diluted EPS
Reported	**$ 2,155**	**$ 1,242**	**$ 112**	**$ 576**	**$ 590**	**(10.5)%**	**$ 1.55**
Reported percent net sales	66.5%	38.3%	3.5%	17.8%	18.2%		
Acquisition and integration-related charges:							
Inventory stepped-up to fair value	(11)	—	—	(11)	(11)	0.3	(0.03)
Other acquisition and integration-related	—	(19)	—	19	17	—	0.05
Amortization of purchased intangible assets	—	—	(112)	112	92	0.5	0.24
Restructuring-related and other charges	4	(35)	—	39	31	0.4	0.08
European Medical Devices Regulation	—	—	—	2	2	—	—
Rejuvenate and other recall-related matters	—	—	—	4	2	0.1	0.01
Regulatory and legal matters	—	(66)	—	66	50	1.0	0.13
Tax matters	—	—	—	—	(130)	24.3	(0.34)
Adjusted	**$ 2,148**	**$ 1,122**	**$ —**	**$ 807**	**$ 643**	**16.1 %**	**$ 1.69**
Adjusted percent net sales	66.3%	34.6%	—%	24.9%	19.8%		

Three Months 2017	Gross Profit	Selling, General & Administrative Expenses	Amortization of Intangible Assets	Operating Income	Net Earnings	Effective Tax Rate	Diluted EPS
Reported	**$ 1,984**	**$ 1,103**	**$ 92**	**$ 525**	**$ 434**	**7.9%**	**$ 1.14**
Reported percent net sales	66.0%	36.7%	3.1%	17.5%	14.4%		
Acquisition and integration-related charges:							
Inventory stepped-up to fair value	2	—	—	2	2	—	0.01
Other acquisition and integration-related	—	(9)	—	9	6	0.2	0.01
Amortization of purchased intangible assets	—	—	(92)	92	66	2.7	0.18
Restructuring-related and other charges	1	(35)	—	36	27	0.7	0.07
Rejuvenate and other recall-related matters	—	—	—	66	48	1.9	0.13
Regulatory and legal matters	—	—	—	—	(5)	1.2	(0.02)
Tax matters	—	—	—	—	—	—	—
Adjusted	**$ 1,987**	**$ 1,059**	**$ —**	**$ 730**	**$ 578**	**14.6%**	**$ 1.52**
Adjusted percent net sales	66.1%	35.2%	—%	24.3%	19.2%		

Nine Months 2018	Gross Profit	Selling, General & Administrative Expenses	Amortization of Intangible Assets	Operating Income	Net Earnings	Effective Tax Rate	Diluted EPS
Reported	**$ 6,482**	**$ 3,668**	**$ 324**	**$ 1,839**	**$ 1,485**	**12.6%**	**$ 3.90**
Reported percent net sales	66.1%	37.4%	3.3%	18.8%	15.1%		
Acquisition and integration-related charges:							
Inventory stepped-up to fair value	—	—	—	—	(4)	0.2	(0.01)
Other acquisition and integration-related	—	(49)	—	49	41	—	0.11
Amortization of purchased intangible assets	—	—	(324)	324	263	0.5	0.69
Restructuring-related and other charges	9	(115)	—	124	98	0.3	0.26
European Medical Devices Regulation	1	—	—	5	4	—	0.01
Rejuvenate and other recall-related matters	—	—	—	10	7	—	0.02
Regulatory and legal matters	—	(121)	—	121	92	0.6	0.24
Tax matters	—	—	—	—	(35)	2.1	(0.09)
Adjusted	**$ 6,492**	**$ 3,383**	**$ —**	**$ 2,472**	**$ 1,951**	**16.3%**	**$ 5.13**
Adjusted percent net sales	66.2%	34.5%	—%	25.2%	19.9%		

Nine Months 2017	Gross Profit	Selling, General & Administrative Expenses	Amortization of Intangible Assets	Operating Income	Net Earnings	Effective Tax Rate	Diluted EPS
Reported	**$ 5,939**	**$ 3,335**	**$ 275**	**$ 1,583**	**$ 1,269**	**10.3%**	**$ 3.34**
Reported percent net sales	66.2%	37.2%	3.1%	17.6%	14.1%		
Acquisition and integration-related charges:							
Inventory stepped-up to fair value	2	—	—	2	2	—	0.01
Other acquisition and integration-related	—	(27)	—	27	20	0.2	0.05
Amortization of purchased intangible assets	—	—	(275)	275	190	3.0	0.50
Restructuring-related and other charges	12	(107)	—	119	95	0.4	0.25
Rejuvenate and other recall-related matters	—	—	—	164	123	1.1	0.33
Regulatory and legal matters	—	(30)	—	30	20	0.4	0.05
Adjusted	**$ 5,953**	**$ 3,171**	**$ —**	**$ 2,200**	**$ 1,719**	**15.4%**	**$ 4.53**
Adjusted percent net sales	66.3%	35.3%	—%	24.5%	19.2%		

Dollar amounts are in millions except per share amounts or as otherwise specified. 16

FINANCIAL CONDITION AND LIQUIDITY

Nine Months	2018	2017
Net cash provided by operating activities	$ 1,564	$ 880
Net cash used in investing activities	(1,229)	(1,153)
Net cash used in financing activities	(951)	(522)
Effect of exchange rate changes on cash and cash equivalents	(8)	71
Change in cash and cash equivalents	**$ (624)**	**$ (724)**

Operating Activities

Cash provided by operating activities was $1,564 and $880 in the nine months 2018 and 2017. The increase was primarily driven by lower Rejuvenate and ABG II recall-related payments, higher net earnings, higher cash receipts related to contracts with customers for unsatisfied performance obligations (partially attributable to ASC 606) and cash receipts from an interest rate hedge settlement partially offset by payments related to the Tax Cuts and Jobs Act of 2017.

Investing Activities

Cash used in investing activities was $1,229 and $1,153 in the nine months 2018 and 2017. The increase in cash used was primarily due to increased payments for acquisitions, primarily the $697 acquisition of Entellus in 2018.

Financing Activities

Cash used in financing activities was $951 and $522 in the nine months 2018 and 2017. The increase in cash used was primarily driven by $313 of higher payments on net borrowings, primarily the refinancing of the $600 senior unsecured notes, $70 higher repurchases of common stock and $51 increase in dividends paid.

Nine Months	2018	2017
Total dividends paid to common shareholders	$ 528	$ 477
Total amount paid to repurchase common stock	$ 300	$ 230
Shares of repurchased common stock (in millions)	1.9	1.9

Liquidity

Cash, cash equivalents and marketable securities were $2,210 and $2,793 on September 30, 2018 and December 31, 2017. Current assets exceeded current liabilities by $3,765 and $4,508 on September 30, 2018 and December 31, 2017. We anticipate being able to support our short-term liquidity and operating needs from a variety of sources including cash from operations, commercial paper and existing credit lines. We raised funds in the capital markets in 2018 and may continue to do so from time to time. We continue to have strong investment-grade short-term and long-term debt ratings that we believe should enable us to refinance our debt as needed.

Our cash, cash equivalents and marketable securities held in locations outside the United States was approximately 30% on September 30, 2018 compared to 62% on December 31, 2017. We intend to use this cash to expand operations organically and through acquisitions.

Critical Accounting Policies

There were no changes to our critical accounting policies from those disclosed in our Annual Report on Form 10-K for 2017.

New Accounting Pronouncements Not Yet Adopted

Refer to Note 1 to our Consolidated Financial Statements for information.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, of a magnitude that we believe could have a material impact on our financial condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of our business, including proceedings related to product, labor, intellectual property and other matters. Refer to Note 6 to our Consolidated Financial Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements referring to us that are not historical facts and are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which are intended to take advantage of the "safe harbor" provisions of the Reform Act, are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include words such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project," "intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results could differ materially and adversely from these forward-looking statements. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include those risks discussed in Item 1A. "Risk Factors" of our Annual Report on Form 10-K for 2017. This Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes to our Consolidated Financial Statements in our Annual Report on Form 10-K for 2017.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We consider our greatest potential area of market risk exposure to be exchange rate risk. Quantitative and qualitative disclosures about exchange rate risk are included in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for 2017. There were no material changes from the information provided therein.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer (the Certifying Officers), evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) at September 30, 2018. Based on that evaluation, the Certifying Officers concluded the Company's disclosure controls and procedures were effective as of September 30, 2018.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial reporting during the three months 2018 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We issued 299 shares of our common stock in the three months 2018 as performance incentive awards to employees. These shares were not registered under the Securities Act of 1933 based on the conclusion that the awards would not be events of sale within the meaning of Section 2(a)(3) of the Act.

In March 2015 we announced that our Board of Directors had authorized us to purchase up to $2,000 of our common stock. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price, and other factors and are subject to regulatory considerations. Purchases are made from time to time in the open market, in privately negotiated transactions or otherwise.

In the three months 2018 we did not repurchase any shares of our common stock. The total dollar value of shares of our common stock that could be acquired under our authorized repurchase program was $1,340 as of September 30, 2018.

ITEM 6. EXHIBITS

2(i)	Agreement and Plan of Merger, dated as of August 29, 2018, by and among Stryker Corporation, Austin Merger Sub Corp. and K2M Group Holdings, Inc. - Incorporated by reference to Exhibit 2.1 to the Company's Form 8-K dated August 30, 2018 (Commission File No. 000-09165)
3(i)†	Restated Articles of Incorporation of Stryker Corporation, dated July 31, 2018
10(i)	Letter Agreement between Stryker Corporation and David Floyd, dated July 6, 2018 - Incorporated by reference to Exhibit 10.1 to the Company's Form 8-K dated July 6, 2018 (Commission File No. 000-09165)
31(i)*	Certification of Principal Executive Officer of Stryker Corporation pursuant to Rule 13a-14(a)
31(ii)*	Certification of Principal Financial Officer of Stryker Corporation pursuant to Rule 13a-14(a)
32(i)*	Certification by Principal Executive Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350
32(ii)*	Certification by Principal Financial Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350
101.INS	XBRL Instance Document
101.SCH	XBRL Schema Document
101.CAL	XBRL Calculation Linkbase Document
101.DEF	XBRL Definition Linkbase Document
101.LAB	XBRL Label Linkbase Document
101.PRE	XBRL Presentation Linkbase Document
	† Filed with this Form 10-Q
	* Furnished with this Form 10-Q

Dollar amounts are in millions except per share amounts or as otherwise specified. 18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STRYKER CORPORATION
(Registrant)

Date: October 26, 2018	/s/ KEVIN A. LOBO Kevin A. Lobo Chairman and Chief Executive Officer
Date: October 26, 2018	/s/ GLENN S. BOEHNLEIN Glenn S. Boehnlein Vice President, Chief Financial Officer

RESTATED ARTICLES OF INCORPORATION
OF
STRYKER CORPORATION

Pursuant to the provisions of Act 284, Public Acts of 1972 (the "Act"), the undersigned corporation executes the following Articles:

1. The present name of the corporation is Stryker Corporation.

2. The identification number assigned by the Bureau is 800151233.

3. The only former name of the corporation was Orthopedic Frame Company.

4. The date of filing the original Articles of Incorporation was February 20, 1946.

5. The following Restated Articles of Incorporation supersede the original Articles of Incorporation as amended and restated to date and shall be the Articles of Incorporation for the corporation.

ARTICLE I

The name of the corporation is Stryker Corporation.

ARTICLE II

The purpose of the corporation is to engage in any activity within the purposes for which corporations may be organized under the Business Corporation Act of Michigan. Without limiting in any manner the scope and generality of the foregoing, the corporation may manufacture and/or sell or lease hospital equipment, medical and surgical supplies and instruments and allied products and may buy, sell, lease or rent real estate and erect buildings in connection with the foregoing, or otherwise.

ARTICLE III

A. The aggregate number of shares of all classes of stock which the corporation shall have authority to issue is 1,000,500,000 to be divided into two classes consisting of 500,000 shares of a class designated "Preferred Stock," of the par value of One Dollar ($1) per share, and 1,000,000,000 shares of a class designated "Common Stock," of the par value of Ten Cents ($0.10) per share.

B. The relative rights, preferences and limitations of the shares of each class are as follows:

1. Preferred Stock. The Preferred Stock may be issued from time to time in one or more series, with such distinctive designation or title and in such number of shares as may be fixed by resolution of the Board of Directors without further action by shareholders. The Board of Directors is expressly granted authority to prescribe, by resolution or resolutions adopted before the issuance of any shares of a particular series of Preferred Stock, the relative rights and preferences of each series, and the limitations applicable thereto, including but not limited to the following:

a. The voting powers, full, special or limited, or no voting powers of each such series;

b. The rate, terms and conditions on which dividends shall be paid, whether such dividends will be cumulative, and what preference such dividends shall have in relation to the dividends on other series or classes of stock;

c. The rights, terms and conditions, if any, for conversion of such series of Preferred Stock into shares of other series or classes of stock;

d. Any right of the corporation to redeem the shares of such series of Preferred Stock, and the price, time and conditions of such redemption, including the provisions for any sinking fund; and

e. The rights of holders of such series of Preferred Stock in relation to the rights of other series and classes of stock upon the liquidation, dissolution or distribution of the assets of the corporation.

Unless the Board of Directors otherwise provides in the resolution establishing a series of Preferred Stock, upon repurchase by the corporation, redemption or conversion, the shares of Preferred Stock shall revert to authorized but unissued shares and may be reissued as shares of any series of Preferred Stock.

2. Common Stock.

a. Subject to the prior payment or provision therefor of dividends on the Preferred Stock, the holders of the Common Stock shall be entitled to receive out of the funds of the corporation legally available for such purpose dividends as and when declared by the Board of Directors.

b. In the event of any liquidation, dissolution or distribution of the assets of the corporation and after satisfaction of the preferential requirements of the Preferred Stock, the holders of Common Stock shall be entitled to share ratably in the distribution of all remaining assets of the corporation available for distribution.

c. The holders of the Common Stock shall be entitled to one vote for each share held by them of record on the books of the corporation.

ARTICLE IV

The shareholders of the corporation shall have no preemptive right to acquire additional or treasury shares of the corporation. All preemptive rights existing prior to the date hereof, whether created by statute or common law, are abolished.

ARTICLE V

The duration of the corporation is perpetual.

ARTICLE VI

The liability to the corporation and its shareholders of each and every person who is at any time a director of the corporation for acts or omissions in such person's capacity as a director is and shall be limited and eliminated to the full extent authorized or permitted by the Michigan Business Corporation Act, as it now exists or may hereafter be amended. Any amendment, alteration or repeal of this Article VI by the shareholders of the corporation shall not adversely affect any right or protection of a director of the corporation for or with respect to any act or omission of such director occurring prior to, or at the time of, such amendment, alteration or repeal.

ARTICLE VII

Each director shall be elected by a majority of the votes cast by the shares represented in person or by proxy and entitled to vote at any meeting for the election of directors at which a quorum is present; provided, however, that if as of the record date for the meeting there are more nominees than positions on the board of directors to be filled by election at such meeting, each director shall be elected by a plurality of the votes cast by the shares represented in person or by proxy at such meeting and entitled to vote on the election of directors. For purposes of this Article VII, a majority of the votes cast means that the number of shares voted "for" a nominee must exceed the number of votes cast "against" that nominee.

6. These Restated Articles of Incorporation were duly adopted on July 31, 2018, by the Board of Directors without a vote of the shareholders pursuant to Section 641(2)(c) of the Act. These Restated Articles of Incorporation only restate and integrate the Articles and include only amendments adopted under Section 611(2) of the Act. There is no material discrepancy between the provisions of the Articles of Incorporation as amended and the provisions of these Restated Articles of Incorporation.

Signed on August 3, 2018.

By: /s/ DEAN H. BERGY

Dean H. Bergy

Vice President, Corporate Secretary

Exhibit 31(i)

CERTIFICATION PURSUANT TO
SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin A. Lobo, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 26, 2018

/s/ KEVIN A. LOBO
Kevin A. Lobo
Chairman and Chief Executive Officer

Exhibit 31(ii)

CERTIFICATION PURSUANT TO
SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Glenn S. Boehnlein, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 26, 2018

/s/ GLENN S. BOEHNLEIN
Glenn S. Boehnlein
Vice President, Chief Financial Officer

Exhibit 32(i)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Stryker Corporation (the "Company") for the quarter ended September 30, 2018 (the "Report"), I, Kevin A. Lobo, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2018

/s/ KEVIN A. LOBO
Kevin A. Lobo
Chairman and Chief Executive Officer

Exhibit 32(ii)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Stryker Corporation (the "Company") for the quarter ended September 30, 2018 (the "Report"), I, Glenn S. Boehnlein, Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2018

/s/ GLENN S. BOEHNLEIN
Glenn S. Boehnlein
Vice President, Chief Financial Officer